SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kosan BioSciences -- KOSN
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
933 40 0 KOSN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
858<i>31% seems excessive. Anyone hear anything else? </i> For whateveSteve Lokness-12/10/2007
857<i>-31% seems excessive. Anyone hear anything else?</i> Yes resp. &Icebrg-12/10/2007
856-31% seems excessive. Anyone hear anything else?keokalani'nui-12/10/2007
855Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple MyelomIcebrg-12/8/2007
854And now Susquehanna with a neutral; biz.yahoo.com <i>AP Sector Snap: BioSteve Lokness-12/7/2007
853Wachovia Starts Kosan Biosciences (KOSN) at Market Perform 12-03-2007 05:42:26 PIcebrg-12/4/2007
852Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and activeIcebrg-12/1/2007
851[Blocking heat shock protein-90 inhibits the invasive properties and hepatic grotuck-11/27/2007
850[Hsp90 inhibitors versus pancreatic cancer] So far as I can remember, the Hsp90tuck-11/3/2007
849[A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility tuck-10/31/2007
848Termination of a Material Definitive Agreement Item 1.02. Termination of a MateIcebrg-10/26/2007
847Kosan to Reacquire Epothilone Program From Roche Thursday October 25, 8:45 pm ETtnsaf-10/25/2007
846[Rituximab and 17-AAG induce synergistic apoptosis in B-cell chronic lymphocytictuck-10/24/2007
845Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epomopgcw-10/23/2007
844FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B,Icebrg-10/17/2007
843Bristol breast cancer drug aims at sickest women Mon Oct 15, 2007 4:52pm By RanIcebrg-10/15/2007
842Johnson filed for a further stock purchase today - 2.000 shares.Icebrg-10/1/2007
841Erik; <i>We also had the strange spike in the share price today. Which laSteve Lokness-9/29/2007
840You should listen to it live (well, recorded), especially since that excerpt fokeokalani'nui-9/29/2007
839Here's the Altus q&a, got to love it. Berkle inspires a lot of confidencrkrw-9/29/2007
838Maybe they listened to the recent ALTU conference call. Accipiter and another Hkeokalani'nui-9/28/2007
837There has been a flurry of Form 4s and amendments - i.e. a couple of them. ReporIcebrg-9/28/2007
836Alvespimycin (KOS-1022) and trastuzumab (T): Activity in HER2+ metastatic breastIcebrg-9/7/2007
835Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Icebrg-9/6/2007
834[17-AAG induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lytuck-9/5/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News